Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Geriatric Medicine
Journal Club ft. NEJM publications
Questions discussed in this category
Do you still plan to offer tofacitinib to RA patients over 65 if they have one or more additional CV risk factors?
2 Answers available
12472
Related Topics in Geriatric Medicine
Primary Care
Neurology
Rheumatology
General Geriatric Medicine
General Internal Medicine
Cardiology
Geriatric Psychiatry
Dementia
General Primary Care
Vascular Neurology
